Updates in Cancer-Associated Thrombosis: Are DOACs Better Than LMWH for Treating Venous Thromboembolism in Cancer Patients
Venous thromboembolism carries a high risk of morbidity and mortality and is the most common type of thromboembolism seen in patients with cancer. Despite this, there are few VTE treatment guidelines targeting this patient group. The program will review recently published guideline updates and new clinical trials regarding direct-acting oral anticoagulants (DOAC) used for treating VTE in patients with cancer. This activity provides an opportunity for pharmacists to apply the most current guidelines and make evidence-based decisions when selecting the most appropriate agent.
Upon completion of this activity, the participant will be able to:
- Describe the epidemiology and pathophysiology of cancer associated thrombosis.
- List anticoagulant options for the treatment of venous thromboembolism (VTE) in patients with cancer.
- Explain literature and guideline updates for the treatment of VTE in patients with cancer.
- Determine appropriate anticoagulation therapy for VTE in patients with cancer.
Hanyu (Diana) Dai, PharmD, is a PGY-1 Resident at Baystate Medical Center in Springfield, MA. She earned her PharmD in May 2020 from the Texas Tech University Health and Sciences Center and Bachelor of Science in Microbiology from the University of Texas at Austin. Diana’s primary areas of interest include oncology, infectious disease, and critical care.
Registration Fee: This module is provided free of charge for all.
Release Date: June 7, 2022
Expiration Date: June 7, 2023
ACPE UAN: 0026-0000-22-132-H01-P | Knowledge
ACPE Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEUs).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Hanyu Dai has no relevant financial relationships with ineligible companies to disclose.
Residency Director Frank Szczerba has no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.